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Inflammation and acinar cell necrosis are twomajor pathological responses of acute pancre-
atitis, a serious disorder with no current therapies directed to its molecular pathogenesis.
Serine/threonine protein kinase D family, which includes PKD/PKD1, PKD2, and PKD3,
has been increasingly implicated in the regulation of multiple physiological and patho-
physiological effects.We recently reported that PKD/PKD1, the predominant PKD isoform
expressed in rat pancreatic acinar cells, mediates early events of pancreatitis including
NF-κB activation and inappropriate intracellular digestive enzyme activation. In current stud-
ies, we investigated the role and mechanisms of PKD/PKD1 in the regulation of necrosis
in pancreatic acinar cells by using two novel small molecule PKD inhibitors CID755673
and CRT0066101 and molecular approaches in in vitro and in vivo experimental models
of acute pancreatitis. Our results demonstrated that both CID755673 and CRT0066101
are PKD-specific inhibitors and that PKD/PKD1 inhibition by either the chemical inhibitors
or specific PKD/PKD1 siRNAs attenuated necrosis while promoting apoptosis induced by
pathological doses of cholecystokinin-octapeptide (CCK) in pancreatic acinar cells. Con-
versely, up-regulation of PKD expression in pancreatic acinar cells increased necrosis and
decreased apoptosis. We further showed that PKD/PKD1 regulated several key cell death
signals including inhibitors of apoptotic proteins, caspases, receptor-interacting protein
kinase 1 to promote necrosis. PKD/PKD1 inhibition by CID755673 significantly ameliorated
necrosis and severity of pancreatitis in an in vivo experimental model of acute pancreatitis.
Thus, our studies indicate that PKD/PKD1 is a key mediator of necrosis in acute pancreatitis
and that PKD/PKD1 may represent a potential therapeutic target in acute pancreatitis.
Keywords: pancreatic acinar cells, CCK, CID755673, CRT0066101, apoptosis, necrosis
INTRODUCTION
Pancreatic acinar cell necrosis is a major pathological response of
acute pancreatitis associated with significant morbidity and mor-
tality from the disease (Gukovskaya andPandol,2004; Pandol et al.,
2007). Currently, there are no therapies directed to the molecular
pathogenesis of necrosis in pancreatitis (Pandol et al., 2007). Thus,
elucidating the molecular signals that mediate acinar cell necrosis
is important for developing new therapeutic strategies.
Apoptosis and necrosis are two major forms of acinar cell death
in acute pancreatitis and associated with specific morphological
and biochemical features (Gukovskaya and Pandol, 2004; Mareni-
nova et al., 2006). Apoptosis is a tightly regulated process involving
the caspase family of cysteine proteases andmanifests as chromatin
condensation, nuclear shrinkage, and reduction in cell volume but
with intact plasma membranes, thus there is no leakage of cellu-
lar contents to the extracellular environment. Conversely, necrosis
leads to early plasma membrane permeabilization and rupture,
cytoplasmic swelling, and release of intracellular constituents to
the extracellular space. There is no sign of nuclear shrinkage
(Gukovskaya and Pandol, 2004; Pandol et al., 2007). Necrosis has
been considered a passive, unregulated form of cell death; how-
ever, recent studies indicate that necrosis can occur in a tightly
regulated fashion, so called as programmed necrosis (Edinger and
Thompson, 2004; Mareninova et al., 2006; Krantic et al., 2007; He
et al., 2009; Moquin and Chan, 2010).
Although the consequences of apoptosis and necrosis are dis-
tinct in pancreatitis, the mechanisms underlying these two types
of cell death are interrelated (Kaiser et al., 1995; Bhatia et al., 1998;
Bhatia,2004a,b;Gukovskaya andPandol,2004;Pandol et al., 2007).
Understanding the regulation of the two death pathways in acute
pancreatitis is important because the severity of acute pancreati-
tis in both humans and in experimental models correlates with
the extent of necrosis (Pandol et al., 2007). In animal models of
pancreatitis the severity also inversely correlates with apoptosis
(Kaiser et al., 1995; Bhatia et al., 1998; Bhatia, 2004a,b; Mareni-
nova et al., 2006). That is, inhibition of apoptosis pathways leads
to necrosis and increased severity of pancreatitis, whereas stimula-
tion of apoptosis attenuates the severity of the disease (Kaiser et al.,
1995; Bhatia et al., 1998; Bhatia, 2004a,b). Therefore, revealing the
key signaling molecules that determine the pattern of pancreatic
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acinar cell death (i.e., apoptosis versus necrosis) in pancreatitis will
provide potential molecular targets for therapy in this disease.
The family of caspases is a major mediator of apoptosis in pan-
creatic acinar cells (Pandol et al., 2007). Caspases are divided into
two classifications.“Effector”caspases (caspase-3, -7) are responsi-
ble for the cleavages that disassemble the cell. “Initiator” caspases
(caspase-8, -9) trigger cleavage and activation of the “effector”
caspases. Activation of both initiator and effector caspases medi-
ates cell apoptosis. Cholecystokinin-octapeptide (CCK-8 orCCK),
at supraphysiologic doses which induces pancreatitis, has been
shown to stimulate the initiator and the effector caspases-8, -9,
and -3 and causes apoptosis of pancreatic acinar cells in vitro and
in vivo experimental pancreatitis (Beil et al., 2002; Gukovskaya
et al., 2002; Bhatia, 2004a; Mareninova et al., 2006; Sung et al.,
2009). Interestingly, increasing evidence (Bhatia, 2004b; Mareni-
nova et al., 2006) indicates that in addition to apoptosis, caspases
also regulate other processes in pancreatitis; in particular, caspases
negatively regulate necrosis. Thus, caspase activation may func-
tion as a critical point switching the cell death response toward
apoptosis and away from necrosis.
NF-κB activation is a key intracellular event in acute pan-
creatitis (Pandol et al., 2007). NF-κB activation is known to
increase the expression of the family of inhibitors of apoptosis
proteins (IAPs; Stehlik et al., 1998; Deveraux and Reed, 1999; Pahl,
1999; Gukovskaya and Pandol, 2004; Zou et al., 2004; Kawakami
et al., 2005; Kerbauy et al., 2005; Pandol et al., 2007), such as X-
linked IAP (XIAP; Stehlik et al., 1998; Deveraux and Reed, 1999;
Gukovskaya and Pandol, 2004) and survivin (Deveraux and Reed,
1999; Kawakami et al., 2005), and anti-apoptotic protein FLICE-
inhibitory protein (c-FLIP; Kerbauy et al., 2005) that inhibit the
caspase system, the essential mediator of apoptotic death path-
ways (Deveraux and Reed, 1999; Tang et al., 2000; Bratton et al.,
2001). The importance of IAPs in regulating the type of death in
pancreatitis has been reported by our group (Mareninova et al.,
2006; Pandol et al., 2007). For example, blocking XIAP resulted
in increased caspase activation and apoptosis while decreasing
necrosis and the severity of pancreatitis.
The mechanisms underlying necrosis are beginning to be
explored. A number of reports indicate that the programmed
necrosis requires the receptor-interacting protein kinase 1 (RIP1;
Lin et al., 1999; Chan et al., 2003; Meylan and Tschopp, 2005; Fes-
tjens et al., 2007; Galluzzi et al., 2009; He et al., 2009; Moquin and
Chan, 2010; Trichonas et al., 2010). RIP1 forms a death-signaling
complex with the Fas-associated death domain and caspases in
response to death domain receptor stimulation (Lin et al., 1999;
Chan et al., 2003; Meylan and Tschopp, 2005; Festjens et al., 2007;
Trichonas et al., 2010). During apoptosis, RIP1 is cleaved and inac-
tivated by caspase-3 and -8 (Lin et al., 1999; Chan et al., 2003;
Moquin and Chan, 2010). The regulation of RIP1 by caspases has
been suggested to be one of mechanisms underlying the protec-
tive role of caspases from necrosis in cerulein-induced pancreatitis
(Mareninova et al., 2006; He et al., 2009).
Serine/threonine protein kinase D family, which includes
PKD/PKD1, PKD2, and PKD3, has emerged as a major target in
the signal transduction pathways induced by G protein coupled
receptor (GPCR) agonists and polypeptide growth factors in a
variety of cell types including pancreatic acinar cells (Berna et al.,
2007; Yuan et al., 2008; Chen et al., 2009; Thrower et al., 2011).
PKD family members are activated through PKC-dependent and
-independent pathways (Matthews et al., 1999; Berna et al., 2007;
Jacamo et al., 2008; Yuan et al., 2008; Chen et al., 2009; Rozengurt,
2011; Thrower et al., 2011) and have been increasingly implicated
in the regulation of multiple cellular functions in health and dis-
ease (reviewed in Rozengurt, 2011), such as protein secretion and
Golgi function, cell proliferation, and apoptosis, oxidative stress
and inflammation, cardiac diseases and cancer (Trauzold et al.,
2003; Storz et al., 2004;Chiu et al., 2007; Fielitz et al., 2008; Sharlow
et al., 2008; Harikumar et al., 2010; Rozengurt, 2011). Particularly,
PKD/PKD1, the predominant PKD isoform expressed in rat pan-
creatic acinar cells (Berna et al., 2007; Yuan et al., 2008) has been
shown to mediate secretagogue-induced signal pathways (Berna
et al., 2007; Yuan et al., 2008; Thrower et al., 2011). We recently
reported that PKD/PKD1 mediates NF-κB activation and inap-
propriate intracellular digestive enzyme activation in pancreatitis
(Yuan et al., 2008; Thrower et al., 2011).
Despite of these studies, the role of PKD/PKD1 in another
critical pathological response in pancreatitis, acinar cell necro-
sis, has not been investigated. Our present study was performed to
determine the role of PKD/PKD1 in cell death responses of acute
pancreatitis. Our findings demonstrate that PKD/PKD1 promotes
necrosis and inhibits apoptosis in pancreatitis through regulation
of IAPs, caspases, and RIP1. In addition, PKD inhibitors signif-
icantly ameliorated necrosis and severity of pancreatitis. Thus,
PKD/PKD1 is a potential therapeutic target in acute pancreatitis.
EXPERIMENTAL PROCEDURES
PREPARATION AND TREATMENTS OF DISPERSED PANCREATIC ACINI
Pancreatic acini were prepared from male Sprague-Dawley rats
(75–100 g) using a collagenase digestion method as described pre-
viously (Yuan et al., 2008; Thrower et al., 2011) and then incubated
in medium 199 supplemented with 0.01% trypsin inhibitor (w/v),
penicillin (100 U/ml), and streptomycin (0.1mg/ml) at 37˚C and
5% CO2-humidified atmosphere. For experimental purposes, the
acini were pre-incubated in the medium 199 with or without
inhibitors and then treated further with cholecystokinin-8 (CCK).
Acini were collected and washed twice with cold PBS.
EXPERIMENTAL PANCREATITIS
Pancreatitis was induced in male (120–150 g) Sprague-Dawley rats
by up to four hourly intraperitoneal (IP) injections of 20 μg/kg
cerulein, a CCK analog used for experimental pancreatitis models.
Control animals received similar injections of physiologic saline.
PKD inhibitor CID755673 (15mg/kg) dissolved in 120–150μl
(15mg/ml) vehicle (DMSO) or same volume DMSO was applied
in rats as a single IP injection 60min before cerulein treatment.
The animals were euthanized by CO2-induced asphyxiation at
30min, and 4 h after the first cerulein injection and then the blood
and pancreas were harvested for measurements. Animal care and
all procedures were approved by the Institutional Animal Care
and Use Committees of the Veterans Affairs Greater Los Angeles
Healthcare System.
QUANTIFICATION OF NECROSIS
Necrosis in pancreatic acini and AR42J cells was determined by
the release of lactate dehydrogenase (LDH) into the incubation
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medium, as previously described (Gukovskaya et al., 1997, 2002;
Gukovskaya and Pandol, 2004; Sung et al., 2009), LDH activity was
measured using Cytotoxicity Detection Kit (Roche Diagnostics,
Indianapolis, IN, USA) according to the manufacturer’s protocol.
Quantification of necrosis in in vivo pancreatitis was per-
formed on pancreatic tissue (collected after four hourly cerulein
injections) sections stained with H&E. Images from multiple ran-
dom,non-overlapping sections were captured under a high-power
field (×400-magnification, 6–10 random fields per section) with
a Nikon Eclipse E600 microscope equipped with a digital cam-
era using the SPOT imaging software (Diagnostic Instruments,
Sterling Heights, MI, USA). Cells with swollen cytoplasm, loss of
plasma membrane integrity, and leakage of organelles into inter-
stitium were considered necrotic. A total of at least 2000 acinar
cells were counted on tissue sections from each animal and three
to five animals per condition were counted.
QUANTIFICATION OF APOPTOSIS
Apoptosis was quantified in pancreatic tissue sections (four hourly
cerulein injections) stained with TdT-mediated dUTP nick end-
labeling (TUNEL) to measure DNA breaks, as we described previ-
ously (Gukovskaya and Pandol, 2004; Mareninova et al., 2006)
using DeadEnd™Fluorometric TUNEL System kit (Promega,
Madison, WI, USA). Briefly, tissue was fixed in 4% buffered
formaldehyde, embedded in paraffin, and 5-μm-thick sections
were adhered to glass slides. Sections were stained using terminal
deoxynucleotidyl transferase and FITC-labeled dUTP according
to the manufacturer’s protocol (Promega, Madison, WI, USA).
Nuclei were counterstained with DAPI. Fluorescence images were
obtained under a high-power field (×400-magnification with a
fluorescence microscope (Nikon Eclipse E600) equipped with a
monochrome camera (CoolSnap, 20MHz; Roper Scientific, Ger-
many) and the MetaMorph imaging system (Universal Imaging
Corporation). Apoptosis was quantified by morphometric analy-
sis of apoptotic acinar cells-stained with bright green relative to
the number of total nuclei-stained with blue using ImageJ 1.42I
software (from NIH). For these and other quantifications of his-
tological measurements, a total of at least 2000 acinar cells were
counted on tissue sections from each animal and three to five
animals per condition were counted.
For the measurement of apoptosis in pancreatic acinar cells, the
isolated pancreatic acinar cells were plated on polylysine-coated
glass coverslips and fixed with methanol at −20˚C for 10min. The
transfected AR42J cells growing on glass coverslips were fixed with
4% formaldehyde in PBS for 25min at 4˚C.Apoptosis of the acinar
cells was quantified by use of TUNEL staining as described above.
A total of at least 3000 acinar cells were counted on the cell smears
for each condition.
Apoptosis of transfected AR42J cell culture was also quanti-
fied by measuring internucleosomal DNA fragmentation using
Cell Death Detection ELISA Plus kit (Roche Molecular Bio-
chemicals, Manheim, Germany) according to the manufacturer’s
instructions.
SERUM AMYLASE AND LIPASE MEASUREMENTS
Animal serum samples were sent to Antech Diagnostics (Irvine,
CA, USA) Custom Service for measurements. The serum amylase
and lipase activities were determined in a Hitachi 707 analyzer
using the company standard enzyme Kinetic methods (assay code
T040 for amylase and T165 for lipase).
HISTOLOGIC ANALYSIS FOR PANCREAS INFLAMMATORY CELL
INFILTRATION, VACUOLIZATION, AND EDEMA
Quantification of inflammatory cell infiltration and vacuolization
was performed on H&E stained pancreatic tissue (four hourly
cerulein injections) sections from at least four rats per group and
expressed as the number of inflammatory cells or vacuoles per
100 acinar cells. Pancreatic edema grading was made from 0 to 3
according to the Schoenberg grading system (Schoenberg et al.,
1990) as 0: no edema; 1: interlobular edema; 2: moderate inter-
lobular and intra-acinar edema; and 3: severe interlobular and
intra-acinar edema.
PKD/PKD1 IMMUNOPRECIPITATION AND IN VITRO KINASE ASSAY
PKD/PKD1 immunoprecipitation and in vitro kinase assay were
performed by the procedures as described previously (Yuan et al.,
2008; Thrower et al., 2011). Briefly, PKD/PKD1 in pancreatic
acinar cell or pancreatic tissue lysates was immunoprecipitated
at 4˚C for 3 h with the PKD/PKD1 C-20 antibody (1:100) and
protein-A-agarose. Exogenous substrate syntide-2 phosphoryla-
tion by immunoprecipitated PKD/PKD1 was carried out by mix-
ing 20μl of the washed immunocomplexes with 10μl of a phos-
phorylation mixture containing 100μM ATP (including [γ-32P]
ATP at 2μCi/assay or with specific activity, 400–600 cpm/pmol)
and 2.5mg/ml syntide-2 (PLARTLSVAGLPGKK) in kinase buffer.
After 10min of incubation at 30˚C, the reaction was stopped by
adding 100μl of 75mM H3PO4, and 75μl of the supernatant was
spotted onP-81 phosphocellulose paper. Free [γ-32P]ATPwas sep-
arated from the labeled substrate by washing the P-81 paper four
times for 5min in 75mM H3PO4. The papers were dried, and
the radioactivity incorporated into syntide-2 was determined by
Cerenkov counting.
MEASUREMENT OF CASPASE ACTIVITIES
Caspase activities were measured using a fluorogenic assay with
substrates specific for caspase-3 (Ac-DEVD-AMC), caspase-8 (Ac-
IETD-AMC), or caspase-9 (Ac-LEHD-AMC) as we described pre-
viously (Mareninova et al., 2006; Sung et al., 2009). Pancreatic
tissue or acinar cell samples were homogenized in a lysis buffer
containing 150mM NaCl, 50mM Tris–HCl (pH 7.5), 0.5% Igepal
CA-630, and 0.5mM EDTA, centrifuged for 15min at 16,000 g,
and the supernatants were collected. Proteolytic reactions were
carried out at 37˚C in a buffer containing 25mM HEPES (pH
7.5), 10% sucrose, 0.1% CHAPS, and 10mM dithiothreitol, using
specific substrates for each caspase. Cleavage of these substrates
relieves 7-amino-4-methylcoumarin (AMC),which emits fluores-
cent signal with excitation at 380 nm and emission at 440 nm.
Fluorescence was calibrated using a standard curve for AMC. The
data are expressed as picomoles of AMC per milligram of protein
per minute.
CELL CULTURE AND TRANSIENT TRANSFECTION
AR42J cells were cultured in F-12K medium supplemented with
20% fetal bovine serum at 37˚C with a humidified atmosphere
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containing 5% CO2. Transfection of AR42J cells with cDNA
plasmids or siRNAs was done using Nucleofector™II (Amaxa
Inc., Gaithersburg, MD, USA) according to the manufacturer’s
protocol.
The plasmid constructs encoding PKD/PKD1, PKD/PKD1
siRNAs Pool (pool of four duplexes; Yuan et al., 2008),
and XIAP siRNAs (pool of three duplexes) were applied
in the transfection. The sequences of the four PKD1 siR-
NAs (sense strands) are as follows: GAAGAGAUGUAGCUAU-
UAA; GAAAGAGUGUUUGUU-GUUA; CAUAAGAGAUGUG-
CAUUUA; and CAGCGAAUGUAGUGUAUUA. The sequences
of the three XIAP siRNAs (sense strands) are GAAUGUUAAU-
GUUCGAAGUtt;GAAUUUCCCAAAUUCAACAtt; andGGAUA-
GAAAUAUUGCUAUAtt. The vector pcDNA3 and siCONTROL
Non-Targeting siRNA Pool (pool of four duplexes) were used as
controls. Three days after transfection, cells were used for experi-
ments. The efficiency of transfection assessed by expression of the
GFP plasmid was 70–80% in AR42J cells.
PREPARATION OF TISSUE AND CELL LYSATES AND WESTERN BLOT
ANALYSIS
Portions of frozen pancreas tissue were homogenized and soni-
cated on ice in lysis buffer as described previously (Yuan et al.,
2008). The tissue lysates were rotated for 40min at 4˚C and cen-
trifuged at 4˚C for 15min at 16,000 g. The supernatants were
collected and stored at −80˚C. Aliquots of the acinar cells were
resuspended in the lysis buffer and processed as described above
for tissue samples. The protein concentration in supernatants was
measured using the Bio-Rad protein assay reagent. Western blot
analyses were performed as described previously (Mareninova
et al., 2006; Yuan et al., 2008; Thrower et al., 2011). The mem-
branes were blocked by 1–2 h incubation with 5% non-fat dried
milk in Tris-buffered saline, pH 7.2, and probed overnight at 4˚C
with specific primary antibodies at a 1:500–1:1000 dilution in the
Tris-buffered saline containing 3% non-fat dried milk. Then the
membranes were incubated with secondary antibodies conjugated
with horseradish peroxidase at 1:5000 dilution for 1 h at room
temperature. Blotsweredevelopedbyusing the enhanced chemilu-
minescence detection kit (Pierce). When reprobing was necessary,
the membrane was stripped of bound antibody by incubating in
Re-Blot Plus Mild Solution (Millipore, Temecula, CA, USA) at
room temperature for 20min.
STATISTICAL ANALYSIS OF DATA
Results are means± SE and represent data from at least three inde-
pendent experiments. The experimental data was evaluated by
the analysis of variance (ANOVA) followed by Bonferroni multi-
ple comparison post hoc tests with the GraphPad Prism software
(GraphPad Software Inc., La Jolla,California).T -tests were used to
analyze differences between two groups. P < 0.05 was considered
statistically significant.
REAGENTS
CCK-8 was from American Peptide (Sunnyvale, CA, USA);
Cerulein was from Peninsula Laboratories (Belmont, CA, USA).
Medium 199 was from GIBCO (Grand Island, NY, USA). AR42J
cell line and medium F-12K were from theAmerican Type Culture
Collection (ATCC; Manassas, VA, USA). Mouse PKD/PKD1 siR-
NAs Pool (pool of 4 duplexes) and siCONTROL Non-Targeting
siRNA Pool were from Dharmacon (Chicago, IL, USA). XIAP
siRNAs were from Invitrogen Life Technologies (Carlsbad, CA,
USA). CRT0066101 was obtained from Cancer Research Technol-
ogy, London, UK. CID755673 was obtained from two sources: a
custom made synthesis from Chem. Div. Res. Ins. (San Diego,
CA, USA) and a commercially available source TOCRIS (MO,
USA). [γ-32P] ATP was from Perkin Elmer (Torrance, CA, USA).
Nitrocellulose membranes were from Schleicher and Schuell Bio-
Science. Carbachol, GF1 (also known as GF 109203X or bisin-
dolylmaleimide I) were from Calbiochem (La Jolla, CA, USA).
Caspase fluorogenic substrates Ac-IETD-AMC, Ac-DEVD-AMC,
and Ac-LEHD-AMC were from Biomol (Plymouth Meeting, PA,
USA).Antibodies against PKD/PKD1C-20, caspase-8, c-FLIP, sur-
vivinwere fromSanta Cruz Biotechnology (Santa Cruz,CA,USA).
Antibodies against phosphoserine 744/748 PKD (predominantly
detects the phosphorylated state of Ser744), phosphoserine 916
PKD, phosphoserine 152/156-MARCKS, XIAP, Cleaved caspase-
3, and GAPDH were obtained from Cell Signaling Technology
(Beverly, MA, USA). phosphoserine 82 Hsp27 was obtained from
ALEXIS Biochemicals (San Diego, CA, USA). Caspase-9 antibody
was from Stressgen (San Diego, CA, USA). RIP1 antibody was
from BD Science (San Diego, CA, USA). Protein-A-agarose was
from Roche Applied Science (Mannheim, Germany) and PKD
substrate, syntide-2, was from Bachem (Chicago, IL, USA). Other
items were from standard suppliers or as indicated in text.
RESULTS
CCK-INDUCED PKD/PKD1 ACTIVATION IS INHIBITED BY PKD
INHIBITORS CID755673 AND CRT0066101 IN PANCREATIC ACINAR CELLS
CID755673 and CRT0066101, two newly developed small mol-
ecule PKD inhibitors, have been demonstrated to inhibit PKD-
mediated cancer growth and other cellular functions (Sharlow
et al., 2008; Harikumar et al., 2010; Thrower et al., 2011). Both
inhibitorswere reported as selective PKD inhibitors (Sharlow et al.,
2008; Harikumar et al., 2010; Thrower et al., 2011). For exam-
ple, their specificity for PKD family members was confirmed in
in vitro kinase assays comprising a panel of 14–90 protein kinases
(Sharlow et al., 2008; Harikumar et al., 2010) including PLK1,
CAK, AKT/PKB, CAMKII, MAPK, MAPKK, c-Raf, c-Src, and c-
Abl (Sharlow et al., 2008; Harikumar et al., 2010). Importantly,
both inhibitors were demonstrated to specifically block PKDactiv-
ity but not suppress its upstream regulators, the PKCs including
PKCα, PKCβ, PKCε, and PKCδ (Sharlow et al., 2008; Harikumar
et al., 2010).
To demonstrate effects of these two PKD inhibitors in pan-
creas, we first examined their specificity for PKD inhibition in
an in vitro experimental pancreatitis model of isolated pancre-
atic acini (Figure 1). Isolated pancreatic acini were pretreated
with CID755673 or CRT0066101 and then stimulated with a
supramaximal dose (100 nM) of the pancreatic secretagogue CCK
which is known to cause cell pathologies of pancreatitis in vitro
(Gukovskaya and Pandol, 2004). We applied 10μM CRT0066101
and 25μM CID755673 for maximal inhibition of PKD activa-
tion based on previous reports including our own measurements
(Sharlow et al., 2008; Harikumar et al., 2010; Thrower et al., 2011).
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FIGURE 1 | CID755673 and CRT0066101 selectively inhibit
supramaximal dose CCK-induced PKD/PKD1 activation in pancreatic
acinar cells. Isolated pancreatic acini were pre-incubated for 3 h with
CID755673 (CID), CRT0066101 (CRT), or GF 109203X (GF1), followed by
incubation with 100 nM CCK for 30min. The acini were collected and lysed.
(A) PKD/PKD1 autophosphorylation at its Ser916 (pS916 PKD1) was
determined byWestern blot analysis of the acinar lysates using
anti-phospho-Ser916 PKD/PKD1 antibody, as described in Section
“Experimental Procedures.” Blots were stripped and re-probed with PKD1
C-20 antibody for loading control. Shown are representative blots from at
least three independent experiments. (B) PKD/PKD1 was
immunoprecipitated from the acini lysate with PKD1 C-20 antibody and the
PKD/PKD1 catalytic activity was measured with in vitro kinase assay as
(Continued)
FIGURE 1 | Continued
described in Section “Experimental Procedures.” Activity values were
normalized by the control without CCK stimulation. Results are means±SE
(n=3) for each condition. **P<0.01 comparing the control versus CCK
alone without inhibitor pretreatments, and comparing CID+CCK or
CRT+CCK versus CCK alone, as indicated with dash lines. (C)Western
blot analyses of the acini lysates with anti-phospho-Ser744/748 PKD or
anti-phospho-Ser152/156-MARCKS antibodies. Blots were stripped and
re-probed with GAPDH antibody for loading controls. (D)Western blot
analyses of the acinar lysates with anti-phospho-Ser82 Hsp27 antibodies.
Blots were stripped and re-probed with Hsp27 antibody for loading controls.
For the current studies, our results showed that CCK-induced
PKD/PKD1 activation dramatically/significantly (∼3- to 4-fold
over the control) measured by both autophosphorylation at
PKD/PKD1 Ser916 with Western blot and an in vitro kinase assay
(Figures 1A,B). Pre-incubation with either 25μM CID755673 or
10μM CRT0066101 almost completely blocked PKD/PKD1 acti-
vation (Figures 1A,B). Of note, the PKD/PKD1 inhibitors did
not affect CCK-induced PKD/PKD1 activation loop (Ser744/748)
phosphorylation (Figure 1C) which is known to result from PKC-
dependent (predominant) and -independent (minor) pathways in
pancreatic acinar cells (Berna et al., 2007;Yuan et al., 2008). But, the
Ser744/748 phosphorylation was largely inhibited by GF109203X
(GF1, 5μM), a conventional and novel PKC inhibitor (Figure 1C).
These results demonstrated the selectivity of our inhibitors for
PKD/PKD1 without an effect on PKC-dependent or -independent
pathways of PKD activation.
Furthermore, we showed that neither CID755673 nor
CRT0066101 blocked phosphorylation of myristolated alanine-
rich C kinase substrate (pS152/156-MARCKS), a known PKC
substrate (Heemskerk et al., 1993; Ramsden, 2000), whereas the
PKC inhibitorGF1 potently blocked the phosphorylation of MAR-
CKS (Figure 1C). Conversely, both CID755673 and CRT0066101
abrogated PKD-dependent phosphorylation of heat shock protein
27 (pS82-Hsp27), a physiologic substrate of PKD/PKD1 (Doppler
et al., 2005; Yuan and Rozengurt, 2008), in pancreatic acini
(Figure 1D). All these results confirmed that both CID755673
and CRT0066101 are PKD-specific inhibitors without an effect on
activities of the PKCs.
PKD/PKD1 REGULATES CELL DEATH PATHWAYS IN PANCREATIC
ACINAR CELLS – PROMOTING CELL NECROSIS AND SUPPRESSING
APOPTOSIS AND CASPASE ACTIVATION
We next investigated the role of PKD/PKD1 in death pathways by
examining the effect of the two PKD inhibitors on cell necrosis
and apoptosis death pathways in pancreatic acinar cells stimulated
with a supramaximal dose of CCK, which serves as an in vitro
experimental pancreatitis model (Figure 2). Isolated pancreatic
acini were pretreated with CID755673 or CRT0066101 for 1 h and
then further incubated with 100 nM CCK for 4 h.
To assess necrosis in pancreatic acini,we measured LDH release
into the extracellular medium. Necrosis is characterized by pro-
gressive cell swelling, rupture of the plasma membrane and, hence,
release of cytoplasmic constituents, particularly, the small mole-
cule protein LDH, in the incubation medium. Thus,measurement
of LDH release into the extracellular medium has been used for
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FIGURE 2 | PKD inhibitors CID755673 and CRT0066101 decrease necrosis
and enhance apoptosis in pancreatic acini induced by supramaximal
dose CCK. Rat pancreatic acini were pre-incubated for 1 h with CID755673
(CID, 25μM) or CRT0066101 (CRT, 10μM), followed by incubation with
100 nM CCK for 4 h. (A) Acinar cell necrosis was measured by the percentage
of total cellular LDH released into the medium, as described in Section
“Experimental Procedures.” (B) Apoptosis was measured by the percentage
of TUNEL staining positive cells. For each condition, at least 3000 cells were
counted. (C) Caspase activities were measured as described in Section
“Experimental Procedures” in the lysates of isolated pancreatic acini. Graphs
(A–C) show mean±SE (n=3–5) for each condition. **P<0.01 comparing the
control versus CCK alone without inhibitor pretreatments as indicated with
dash lines; *P <0.05 comparing CID+CCK or CRT+CCK versus CCK alone
without inhibitor.
measuring necrosis of isolated pancreatic acini in multiple stud-
ies of pancreatitis (Gukovskaya et al., 1997, 2002; Gukovskaya and
Pandol, 2004; Sung et al., 2009). LDH levels in both cell lysate and
medium samples were assayed and the results were expressed as
the percent of cellular LDH released into the medium.
Our results showed that either CID755673 or CRT0066101
alone did not effect on the basal level of LDH release, which was
in accordance with our previous report (Thrower et al., 2011).
Importantly, pretreatment of the acinar cells with CID755673 or
CRT0066101 significantly reduced supramaximal dose of CCK-
induced necrosis after 4 h stimulation (Figure 2A). Of note, our
previous results from 2 h of incubation of CCK in PKD/PKD1
inhibitor CRT0066101-treated pancreatic acini already showed a
small decrease in LDH release (Thrower et al., 2011). The differ-
ence with the present results from 4 h of incubation with CCK
suggests that the necrosis effect of CCK is time-dependent, thus
the inhibitors show greater benefit with a longer duration of
incubation.
Next, we determined the effect of the two PKD inhibitors on
apoptosis of the isolated acini. Distinct from necrosis, there is
no leakage of cellular contents to the extracellular environment
in apoptosis. The features of morphologic changes in apoptosis
include shrinkage of the cell and its organelles and condensation
of nuclear chromatin followed by intranucleosomal DNA cleav-
age. Thus, we measured CCK-stimulated acinar cell apoptosis by
measuring DNA breaks, a biochemical hallmark of apoptosis, with
a TUNEL assay. Our results showed that in contrast with their sup-
pressing effect on CCK-induced necrosis, the two PKD inhibitors
both promoted CCK-stimulated acinar cell apoptosis (Figure 2B)
but had no effect on the basal apoptosis.
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Apoptosis in pancreatic acinar cells is mediated mainly by acti-
vation of caspases. Supramaximal dose (100 nM) of CCK has been
known to activate initiator and effector caspases-8, -9, and -3 and
cause apoptosis of pancreatic acinar cells in pancreatitis (Beil et al.,
2002; Gukovskaya et al., 2002; Bhatia, 2004a; Mareninova et al.,
2006; Sung et al., 2009).We here determined whether the two PKD
inhibitors promote apoptosis through effect on caspase activation.
Similarly to the previous results (Beil et al., 2002; Gukovskaya
et al., 2002; Mareninova et al., 2006; Sung et al., 2009), we also
observed that 100 nM CCK caused activation of caspases-8, -9,
and -3 in pancreatic acinar cells (Figure 2C). More importantly,
in the acini pre-incubated with either PKD inhibitor, CID755673
andCRT0066101 both exerted a proapoptotic effect, i.e., enhanced
the activation of these caspases induced by a supramaximal dose
CCK (Figure 2C).
Thus, with the two PKD/PKD1 inhibitors we demonstrated
that PKD/PKD1 regulates cell death in pancreatic acinar cells
by promoting cell necrosis while suppressing apoptosis/caspase
activation. These findings prompted us to evaluate the potential
anti-necrotic effect of PKD/PKD1 inhibitors in vivo. Due to its
availability, we choose CID755673 for our in vivo experimental
pancreatitis model.
CID755673 AMELIORATES NECROSIS AND OTHER PANCREATITIS
PARAMETERS IN CERULEIN-INDUCED PANCREATITIS
We first tested dose- and time-dependency of the effect of
CID755673 pretreatment on PKD/PKD1 catalytic activation in
a CCK analog (cerulein)-induced pancreatitis to find an opti-
mal dose of the inhibitor and the interval time between the
inhibitor injection and cerulein injection for maximum inhibition
of PKD/PKD1. Three doses of the inhibitor (10, 15,or 20mg/kg) at
different pretreatment lasting time (30, 45, or 60min) were tested.
Rats first received an IP injection of CID755673 at a certain dose
(10, 15, or 20mg/kg). The control animals received same volume
of vehicle. After a different waiting time (30, 45, or 60min), the
inhibitor- or vehicle-pretreated animals were given an IP injection
of cerulein or saline. Each combination of the inhibitor pretreat-
ment (dose and time) was performed on three rats. The pancreas
was collected in 30min after the cerulein injection.
PKD/PKD1 catalytic activity in the pancreatic tissue lysate was
measured by in vitro kinase assays. Figure 3A showed that ∼50–
60% of cerulein-induced PKD/PKD1 activation was inhibited by
30min-pretreatment of the animals with CID 755673 at a dose
of 15mg/kg. PKD/PKD1 activation was almost abolished with
60min of pretreatment (close to basal level) at this dose. Sim-
ilar results were also observed in animals pretreated with CID
755673 at a dose of 20mg/kg, but less than 50% inhibition of
PKD/PKD1 activity was achieved with a lower dose (10mg/kg) of
CID755673 at this time point (data not shown). Thus, we decided
to use 15mg/kg CID755673 and the time (60min) for animal pre-
treatmentwith the inhibitor prior to cerulein injection throughout
this study.
Corresponding to its inhibition to PKD/PKD1 catalytic activ-
ity, pretreatment of rats with CID755673 for 60min also blocked
PKD/PKD1 Ser916 autophosphorylation (Figure 3B). Of note,
similar to the results from in vitro experiments, in vivo treat-
ment with CID755673 had no effect on PKD/PKD1 Ser744/748
phosphorylation which was predominantly PKC-dependent and
on phosphorylation of PKC substrate (pS152/156-MARCKS) in
pancreatitis (Figure 3C) while CID755673 treatment blocked
phosphorylation of PKD/PKD1 substrate (pS82-Hsp27) in pan-
creatitis (Figure 3D), confirming the specificity of CID755673
targeting PKD/PKD1 in vivo.
Next, we evaluated the effect of PKD/PKD1 inhibition on the
parameters of cerulein-induced pancreatitis. After 1 h pretreat-
ment of CID755673 (15mg/kg) or vehicle as described above,
the rats received up to four hourly IP injections of cerulein or
saline. The animals were sacrificed at 30min and 4 h after the
first cerulein injection. As illustrated in Figure 4A, cerulein caused
striking increases of blood amylase and lipase after four hourly
IP injections of cerulein, which were significantly attenuated in
CID755673-treated rats. Furthermore, CID755673 treatment dra-
matically ameliorated the histological damage in cerulein-induced
pancreatitis (Figure 4B). The salient feature of pancreas histolog-
ical changes in CID755673-pretreated animals was that cerulein-
induced severe acinar cell necrosis was strikingly attenuated and
almost prevented (Figure 4C). Other histopathologic features of
pancreatitis including interstitial edema, accumulation of cyto-
plasmic vacuoles, and inflammatory cell infiltration were also
greatly attenuatedbyCID755673 treatment (Figures 4D–F). These
results from the in vivo pancreatitis model demonstrated that
PKD/PKD1 inhibition blocks necrosis and ameliorates severity
of acute pancreatitis.
CID755673 INCREASES APOPTOSIS AND CASPASE ACTIVITIES IN
CERULEIN-INDUCED PANCREATITIS
We then investigated the effects of CID755673 on apoptosis in
cerulein-induced pancreatitis (Figure 5A). The in situ TUNEL
assays showed that cerulein-induced apoptosis increased two
fold in CID755673-pretreated rats compared with the controls
(Figure 5B). This data confirmed our in vitro experimental results
demonstrating the proapoptotic effect of CID755673 on acinar cell
death in pancreatitis. Combinationof the results of theCID755673
effects on the two death pathways (necrosis versus apoptosis)
shows that the ratio of necrosis/apoptosis in cerulein-induced
pancreatitis was dramatically decreased (∼10 times less) in the
CID755673-treated rats (Figure 5C).
Next, we measured caspase activities in pancreas tissue
homogenates. The activities of caspase -3, -9, and -8 were all sig-
nificantly increased in CID755673-treated rats at either early stage
(30min) or late stage (4 h) of cerulein-induced pancreatitis com-
pared with the non-inhibitor-treated controls (Figure 5D). These
results indicated that the PKD inhibitor shifts necrosis to apop-
tosis in pancreatitis by removing the blockade of PKD/PKD1 on
caspase activation.
GENETIC REGULATION OF PKD/PKD1 EXPRESSION ALTERS CELL DEATH
PATHWAYS IN PANCREATIC ACINAR CELLS
Although the combination of our in vitro and in vivo experi-
ments with the two pharmacological inhibitors of PKD shows
that PKD/PKD1 plays a critical role in regulation of cell death in
pancreatitis, we further validate the function of PKD/PKD1 by
altering PKD/PKD1 expression with molecular approaches in the
cell culture model of pancreatic acinar AR42J cells (Piiper et al.,
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FIGURE 3 | CID755673 pretreatment inhibits PKD/PKD1 activation in
pancreatic tissue in cerulein-induced pancreatitis. (A) Rats received
intraperitoneal (IP) injection of CID755673 (CID, 15mg/kg) or same volume
of vehicle DMSO. After 30, 45, or 60min waiting time, the inhibitor- or
vehicle-pretreated animals were given an IP injection of cerulean (CR) or
saline (S). The pancreas was collected in 30min after the cerulein or saline
injection. The pancreas tissue lysates were immunoprecipitated with
PKD/PKD1 C-20 antibody and PKD1 activity in the immunocomplexes was
determined by in vitro kinase assay. PKD/PKD1 catalytic activities were
expressed as percentage of maximum activity in the animals injected with
cerulein without inhibitor pretreatment. Results are means±SE (n=3) for
(Continued)
FIGURE 3 | Continued
each condition. *P <0.05 versus cerulein alone without inhibitor
pretreatments. (B–D)The pancreas tissue was collected in 30min after
cerulein injection in rats pretreated for 60min with CID755673 as described
above and the tissue lysates were analyzed byWestern blot using
antibodies against phospho-Ser916 PKD1 (B), phospho-Ser744/748 PKD1 or
phospho-Ser152/156-MARCKS (C), or phospho-Ser82 Hsp27 antibodies
(D). The blots were then reblotted with antibodies against PKD1 C-20 or
GAPDH to verify equal protein loading.
2001). AR42J cells were transfected with pooled PKD1siRNAs
(four duplexes) or pcDNA3-PKD1 vector. Control cells received
non-target (NT) siRNAs or empty vector (pcDNA3). After 3 day
incubation in cell culture medium, PKD/PKD1 protein expres-
sion and CCK-induced PKD/PKD1 activation was analyzed
with Western blot analysis of the transfected cell lysates. The
results confirmed that PKD/PKD1 expressionwas down-regulated
in PKD1siRNAs-transfected cells but dramatically increased in
pcDNA-PKD1-transfected cells (Figure 6A). Similarly to our pre-
viously reported results (Yuan et al., 2008), CCK-induced PKD1
activation was correlated with its expression levels. That is, CCK-
induced PKD/PKD1 activation was markedly enhanced in cells
overexpressing PKD1 but was dramatically decreased in cells with
PKD1 knocked down (data not shown).
We then measured cell necrosis and apoptosis after the trans-
fected cells were incubated for 5 h with 100 nM CCK. As shown
in Figure 6B, cell incubation with CCK caused an increase in
cellular LDH release (a measure of necrosis) in control cells
(NTsiRNAs, pcDNA cells). Importantly, inhibition of PKD/PKD1
expression byPKD1siRNAs attenuatedCCK-induced cell necrosis.
Conversely, CCK-induced cell necrosis was significantly enhanced
in PKD/PKD1-overexpressing cells. In contrast to its stimulat-
ing effect on necrosis, increased PKD/PKD1 expression resulted
in inhibition of CCK-stimulated apoptosis while PKD/PKD1
down-regulation caused dramatically increased CCK-induced
apoptosis determined by measuring internucleosomal DNA frag-
mentation with ELISA and by cell staining with TUNEL assay
(Figure 6C). Interestingly, PKD/PKD1 overexpression or knock-
down also affected the basal necrosis and apoptosis rates of the
transfected cells.
Furthermore, we found that PKD/PKD1 down-regulation by
PKD1siRNAs promoted CCK-induced activation of caspase-3, -9,
-8, whereas PKD/PKD1 overexpression markedly inhibited these
caspases (Figure 6D). Thus, with molecular approaches we con-
firmed that PKD/PKD1 promotes cell necrosis while suppresses
apoptosis and caspase activation in pancreatic acinar cells.
PKD/PKD1 INHIBITION DECREASES ANTI-APOPTOTIC PROTEIN LEVELS
IN CERULEIN-INDUCED PANCREATITIS
Inhibitors of apoptosis proteins are potent endogenous suppres-
sors of apoptosis and function by directly inhibiting the activ-
ity of caspases (Stehlik et al., 1998; Deveraux and Reed, 1999;
Gukovskaya and Pandol, 2004; Kawakami et al., 2005; Kerbauy
et al., 2005;Mareninova et al., 2006;Pandol et al., 2007).Awealth of
evidence indicates that IAPs, such as XIAP and survivin, play a piv-
otal role in regulation of cell death (Stehlik et al., 1998; Deveraux
and Reed, 1999; Pahl, 1999; Zou et al., 2004; Kawakami et al., 2005;
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FIGURE 4 | PKD/PKD1 inhibition by CID755673 ameliorates necrosis
and other pancreatitis parameters in cerulein-induced pancreatitis.
Rats received intraperitoneal (IP) injection of CID755673 (CID, 15mg/kg) or
same volume of vehicle DMSO. At 60min after the pretreatment,
pancreatitis was induced by four hourly IP injections of cerulein (CR), as
described in Section “Experimental Procedures.” Control rats received
saline (S). The blood and pancreas were harvested in 4 h after the first
injection of cerulein for the following measurements. (A) Serum amylase
and lipase levels were measured. (B) H&E staining of pancreatic tissue
sections from the experiments. Each image is representative of at least 6
rats with similar results at each condition. Bars represent 20μm. (C)
Necrosis was measured on H&E stained pancreatic tissue sections. Cells
with swollen cytoplasm, loss of plasma membrane integrity, and leakage of
organelles into interstitium were considered necrotic. For necrosis
measurement and the quantifications of following other histological
measurements, a total of at least 2000 acinar cells were counted on tissue
sections from each animal and three to five animals each condition were
(Continued)
FIGURE 4 | Continued
counted. (D) Pancreatic edema grading was made from 1 to 3 on the H&E
stained tissue sections with Schoenberg grading system as described in
Section “Experimental Procedures.” (E,F) Number of vacuole and
inflammatory cell infiltration were counted on these H&E stained
pancreatic tissue sections and expressed as percentage of total acinar
cells. Graphs (A,C–F) show means±SE (n=4) for each condition.
**P<0.01 or *P<0.05 versus cerulein alone without inhibitor
pretreatments as indicated.
Kerbauy et al., 2005; Harikumar et al., 2010). To further explore
the signal pathwaysmediating the regulation of PKD/PKD1on cell
death, we hypothesized that PKD/PKD1 blocks caspase activation
through regulating IAPs in pancreatitis.
We first determined whether PKD/PKD1 regulates XIAP,
the most potent among the eight mammalian IAPs (Stehlik
et al., 1998; Zou et al., 2004) and an endogenous inhibitor
of caspase-9 and -3, in in vivo experimental pancreatitis. Our
previous report (Mareninova et al., 2006) showed that rate of
XIAP degradation during cerulein-induced pancreatitis is a key
determinant of the type of cell death and that pharmacolog-
ical inhibition of XIAP ameliorated necrosis and severity of
cerulein-induced pancreatitis. Here we found that PKD1 inhibi-
tion by CID755673 altered protein levels of XIAP in cerulein-
induced pancreatitis (Figure 7A). Although both non-inhibitor-
treated and inhibitor-treated groups exhibited XIAP degradation
in pancreatitis after four hourly cerulein injections, of impor-
tance, XIAP in CID755673-treated rats was degraded earlier
(in 30min after first cerulein injection) and to a much greater
extent than in non-inhibitor-treated animals, indicating that
the PKD/PKD1 inhibition promotes degradation of XIAP in
pancreatitis.
We next examined whether c-FLIP and survivin, the other
two anti-apoptotic proteins (Kawakami et al., 2005; Kerbauy
et al., 2005), are also altered in pancreatitis. c-FLIP, an impor-
tant endogenous protein inhibitor of caspase-8, has two splice
isoforms: c-FLIPS (short) and c-FLIPL (long). c-FLIPS completely
inhibits caspase-8 processing, whereas c-FLIPL allows partial pro-
cessing of caspase-8 (Krueger et al., 2001; Thome and Tschopp,
2001; Peter, 2004). We found that both c-FLIPS and c-FLIPL were
markedly up-regulated in pancreatitis (Figure 7B). There was
no significant difference in the magnitude of the up-regulation
of c-FLIPL between non-inhibitor and inhibitor-treated groups.
However, the up-regulation of c-FLIPS, which can completely
block caspase-8 processing, was much earlier (in 30min after first
cerulein injection) and to a greater extent in non-inhibitor-treated
rats than in inhibitor-treated rats (Figure 7B), indicating that the
PKD/PKD1 inhibitor CID755673 suppressed the up-regulation of
c-FLIPS in pancreatitis. Further,we found a significantly decreased
protein level of survivin, an endogenous inhibitor of caspase-3,
after four hourly cerulein injections in CID755673-treated rats
(Figure 7C).
Thus, our in vivo experimental results indicate that inhibi-
tion of PKD/PKD1 has significant effects on these endogenous
protein inhibitors of caspases, including XIAP, c-FLIPs, and sur-
vivin, accounting for the effects observed on caspase activation
and apoptosis in vivo and indicating that CID755673 ameliorated
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FIGURE 5 | CID755673 enhances apoptosis and caspase activation in
cerulein-induced pancreatitis. (A) In situ TUNEL staining of apoptotic
acinar cells (green staining, pointed with arrows) in pancreatic tissue
sections from the experiments. Nuclei were counterstained with DAPI
(blue staining). Fluorescence images were obtained under a high-power
field (×400-magnification with a fluorescence microscope (Nikon Eclipse
E600) equipped with a monochrome camera (CoolSnap, 20MHz; Roper
Scientific, Germany) and the MetaMorph imaging system (Universal
Imaging Corporation). Each image is representative of at least 6 rats with
similar results at each condition. Bars represent 20μm. (B) Apoptosis
were quantified by morphometric analysis of apoptotic acinar
cells-stained with bright green relative to the total nuclei number (blue)
using ImageJ 1.42I software (from NIH) on pancreatic tissue sections
from rats with 4 h injections of cerulein (CR) and saline (S). A total of at
least 2000 acinar cells were counted on tissue sections from each
animal and 3–5 animals per condition were counted. (C)
Necrosis/apoptosis ratios were compared in the groups of rats with and
without CID pretreatment. The ratio calculation was based on the
percentage of necrotic cells versus percentage of apoptotic cells using
the data from (A) and Figure 4C. (D) Caspase activities at the indicated
time points were measured in pancreatic tissue homogenates. Graphs
(B,D) show means±SE (n=3). **P<0.01 or *P<0.05 versus cerulein
alone without inhibitor pretreatments (CR+DMSO) or versus control
without cerulein (DMSO) as indicated.
necrosis in pancreatitis probably through suppressing the levels of
these IAP proteins.
PKD/PKD1 INHIBITION PROMOTES DEGRADATION OF RIP1 IN
CERULEIN-INDUCED PANCREATITIS
Receptor-interacting protein kinase has recently emerged as a key
mediator of programmed necrosis in acute pancreatitis (Mareni-
nova et al., 2006; He et al., 2009) and other diseases (Lin et al.,
1999; Chan et al., 2003; Meylan and Tschopp, 2005; Festjens et al.,
2007; Galluzzi et al., 2009; Moquin and Chan, 2010; Trichonas
et al., 2010). RIP1 forms a death-signaling complex with the Fas-
associated death domain and caspases in response to death domain
receptor stimulation (Lin et al., 1999;Chan et al., 2003;Meylan and
Tschopp, 2005; Festjens et al., 2007; Trichonas et al., 2010). Dur-
ing apoptosis, RIP1 is cleaved and inactivated by caspase-3 and
-8 (Lin et al., 1999; Chan et al., 2003; Moquin and Chan, 2010).
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FIGURE 6 | Effects of genetic down- or up-regulation of PKD/PKD1
expression on cell necrosis and apoptosis/caspase activation in AR42J
cells induced by supramaximal dose CCK. AR42J cells were transfected
with pooled four PKD1 siRNA duplexes or pcDNA3-PKD1 vector. Control cells
received non-target (NT) siRNAs or empty vector (pcDNA3). (A)Western blot
analysis of the transfected AR42J cell lysates using PKD1 C-20 antibody to
measure PKD/PKD1 expression and using GAPDH antibody to verify equal
loading. Shown are representative blots from at least 3 independent
experiments.The band densities were normalized with corresponding controls
(PKD1 siRNA versus NT siRNAs; pcDNA-PKD1 versus pcDNA). (B)The
transfected cells were incubated in serum-free F-12K medium for 1 h and then
incubated for 5 h with or without 100 nM CCK. Cell necrosis was measured by
the percentage of total cellular LDH released into the extracellular medium.
Results are expressed as the percentage of total cellular LDH released into
the medium. (C) Apoptosis was quantified by two methods: Upper panel,
measuring internucleosomal DNA fragmentation using Cell Death Detection
ELISA Plus kit according to the manufacturer’s instructions. Results are
expressed as increase fold over control in DNA fragmentation; Lower panel,
the transfected AR42J cells growing on glass coverslips were fixed and
apoptosis was measured by the percentage of TUNEL staining positive cells.
For each condition, at least 3000 cells were counted. (D) Caspase activities
were measured as described in Section “Experimental Procedures.” Graphs
(B–D) show means±SE (n=3–5) for each condition. *P<0.05 versus
corresponding controls (NT siRNA or pcDNA3) as indicated.
The regulation of RIP1 by caspases has been suggested to be one
of mechanisms underlying the protective role of caspases from
necrosis in cerulein-induced pancreatitis (Mareninova et al., 2006;
He et al., 2009).
For the present study,we determined the effect of the inhibition
of PKD/PKD1 on RIP1 degradation. In agreement to our previous
findings (Mareninova et al., 2006), RIP1 underwent cleavage to a
47-kDa product after four hourly cerulein injections (Figure 7D).
The salient feature of the present results was that the cleavage of
RIP1 started earlier (in first cerulein injection) and progressed to
a greater extent in inhibitor-treated rats than in non-inhibitor-
treated animals. The results with RIP1 during PKD/PKD1 inhibi-
tion correlated with the changes in caspase activities (Figure 5D)
and cleavage of IAPs (Figures 7A–C). These findings suggest that
PKD/PKD1-regulated IAPs/caspases pathways play a role in RIP1
cleavage/inactivation in cerulein-induced pancreatitis.
PKD/PKD1REGULATES PROTEIN LEVELS OF IAPs AND RIP1 IN
PANCREATIC ACINAR CELLS
To provide insights into the mechanism of effects of PKD/PKD1
on IAPs and RIP1, we examined whether genetic regulation of
PKD/PKD1 expression alters protein levels of IAPs and RIP1 in
pancreatic acinar cells. We found that cells transfected with PKD1
siRNAs markedly down-regulated PKD/PKD1 expression, which
resulted in dramatically decreased protein levels of XIAP, survivin,
and FILPs (Figure 8A). Conversely, overexpression of PKD/PKD1
enhanced the levels of these IAPs (Figure 8B). Furthermore, up-
regulation of PKD1 expression promoted RIP1 production and
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FIGURE 7 | Effect of CID755673 on anti-apoptotic proteins levels and
degradation of RIP1 in cerulein-induced pancreatitis.Western blot analysis
of pancreas tissue lysate using antibodies against XIAP (A), cFLIP (B),
survivin (C), and RIP1 (D) to measure the protein levels of these proteins at
early (30min) and late (4 h) stages of cerulein (CR)-induced pancreatitis. Blots
were re-probed for GAPDH to confirm equal protein loading. The bar figures
are the quantification of these protein band intensities that were normalized
on the band intensity in control animals injected with saline (S). Graphs show
means±SE (n=4) for each condition. *P <0.05 versus cerulein alone
(DMSO+CR) in first injection and fourth injection (#).
inhibited CCK-induced RIP1 cleavage/inactivation (Figure 8C)
whereas knockdown PKD1 promoted RIP1 cleavage/inactivation
(Figure 8D). These findings confirmed that PKD/PKD1 regulates
IAPs and RIP1 protein levels, as observed in cerulein-induced
pancreatitis.
Thus, with pharmacologic and genetic approaches, we have
demonstrated that PKD/PKD1 mediates cell necrosis in pancre-
atitis through regulating IAPs, caspases, and RIP1.
GENETIC INHIBITION OF XIAP STIMULATES APOPTOSIS AND CASPASE
ACTIVATION WHILE PROMOTING RIP1 DEGRADATION AND
ATTENUATING NECROSIS
Next, to further confirm the pivotal role of IAPs in cell death in
pancreatitis, we assessed whether the down-regulation of XIAP,
the major IAP, affects cell death pathways and RIP1 inacti-
vation. We transfected AR42J cells with pooled XIAP siRNAs
(three siRNA duplexes) to suppress XIAP protein expression, as
confirmed with Western blot analysis (Figure 9A). Interestingly,
specific inhibition of the expression of this endogenous inhibitor
of caspases resulted in not only increased apoptosis and cas-
pase activation (Figure 9B) but also a dramatically attenuated
CCK-induced cell necrosis (Figure 9C). These results support
our previous findings that caspases protect from necrosis in pan-
creatitis (Mareninova et al., 2006) and support the importance
of PKD/PKD1-regulated IAPs/caspases pathways in mediating
necrotic death pathways in pancreatitis.
We then examined whether XIAP regulates RIP1 cleavage. Inhi-
bitionof XIAP expressionwith specific siRNAsmarkedly increased
RIP1 cleavage/inactivation in the transfected cells (Figure 9D).
These results indicate that similar to PKD/PKD1, XIAP negatively
regulates RIP1 cleavage and inactivation. The negative regulation
of RIP1 cleavage or inactivation by both PKD/PKD1 and XIAP
suggest that one mechanism by which PKD1/IAPs signaling path-
way promotes necrotic cell death in acute pancreatitis is through
preventionof RIP1 cleavage/inactivation.We summarize the signal
pathways in Figure 10.
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FIGURE 8 | Effects of genetic down- or up-regulation of PKD/PKD1
expression on protein levels of IAPs and RIP1. AR42J cells were
transfected with pooled four PKD1 siRNA duplexes or pcDNA3-PKD1 vector.
Control cells received non-target (NT) siRNAs or empty vector (pcDNA3).
Three days after transfection, the cells were incubated in serum-free F-12K
medium for 1 h and then incubated for 5 h with or without 100 nM CCK. (A,B)
Western blot analysis of the transfected AR42J cell lysates using antibodies
against PKD1 C-20, XIAP, survivin, and FLIP to show effects of down- or
up-regulation of PKD/PKD1 expression on the protein levels of these IAPs.
Blots were re-probed for GAPDH to confirm equal protein loading. Shown are
representative blots from at least three independent experiments. (C,D)
Western blot analysis of the cell lysates using RIP1 antibody to detect the
effect of up-regulation or knockdown of PKD/PKD1 expression on RIP1
expression and cleavage. The membranes were reblotted with GAPDH
antibody to verify equal loading. Shown are representative blots from three
independent experiments.
DISCUSSION
PKD/PKD1 has been shown to mediate NF-κB activation and
inappropriate intracellular digestive enzyme activation in pan-
creatitis (Yuan et al., 2008; Thrower et al., 2011), but its role in
regulation of cell necrosis in pancreatitis has not been investi-
gated. The studies presented here demonstrate that PKD/PKD1
activation promotes necrosis and inhibits apoptosis in both in vitro
and in vivo models of pancreatitis. In vivo treatment of animals
with PKD/PKD1 inhibitor CID755673 significantly ameliorated
necrosis and the severity of pancreatitis.
Apoptosis in pancreatic acinar cells is mediated mainly by
activation of caspases. Of importance, it has been increasingly
recognized that caspases not only mediate apoptosis but also
protect from necrosis and decrease the severity of pancreati-
tis (Bhatia, 2004a; Gukovskaya and Pandol, 2004; Mareninova
et al., 2006; Pandol et al., 2007). We found that up-regulation
of PKD/PKD1 expression prevented CCK/cerulein-induced acti-
vation of caspase-9, -8, and -3 and promoted necrosis. On the
other hand, inhibition of PKD/PKD1 enhanced the activation
of caspases in both in vitro and in vivo models of pancreatitis,
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FIGURE 9 | Inhibition of XIAP expression stimulates apoptosis and
caspase activation while promoting RIP1 degradation and attenuating
necrosis induced by CCK. AR42J cells were transfected with non-target
(NT) or pooled XIAP siRNAs (three siRNA duplexes) as indicated. The
transfected cells were incubated in serum-free F-12K medium for 1 h and
then incubated for 5 h with or without 100 nM CCK. (A)Western blot
analysis of the cell lysates using XIAP antibody for XIAP expression and
using GAPDH antibody to verify equal loading. Shown are representative
blots from at least three independent experiments. (B) Apoptosis quantified
by measuring internucleosomal DNA fragmentation, as described in Section
“Experimental Procedures.” Results are expressed as increased fold over
control. Caspase activities were measured as described in Section
“Experimental Procedures” for the lysates of transfected AR42J cells. (C)
Cell necrosis was measured by the percentage of total cellular LDH
released into the extracellular medium. Graphs (B,C) show means±SE
(n=3 to 4) for each condition. **P<0.01 or *P<0.05 versus each
corresponding NTsiRNA control with CCK-treated, as indicated. (D)Western
blot analysis of the cell lysates using RIP1 antibody for RIP1 protein level
and degradation and using GAPDH antibody to verify equal loading. Shown
are representative blots from three independent experiments.
resulting in decreased necrosis and the severity of pancreati-
tis. Therefore, the pro-necrosis effect of PKD/PKD1 activa-
tion in pancreatitis is mediated through inhibition of caspase
activation.
NF-κB-dependent anti-apoptotic gene products are an impor-
tant class of endogenous protein inhibitors of caspase activation
(Stehlik et al., 1998; Deveraux and Reed, 1999; Pahl, 1999; Bratton
et al., 2001; Zou et al., 2004; Kawakami et al., 2005; Kerbauy et al.,
2005; Pandol et al., 2007). Transcriptional activation of XIAP, sur-
vivin, and c-FLIP throughNF-κBpathways has beendemonstrated
to be crucial in regulating cell death (Stehlik et al., 1998; Dever-
aux and Reed, 1999; Pahl, 1999; Bratton et al., 2001; Zou et al.,
2004; Kawakami et al., 2005; Kerbauy et al., 2005; Mareninova
et al., 2006; Pandol et al., 2007), including pancreatitis (Mareni-
nova et al., 2006; Pandol et al., 2007). We previously demonstrated
that PKD/PKD1 is required for NF-κB activation in pancreatic
acinar cells (Yuan et al., 2008) and that CCK-induced NF-κB acti-
vation is significantly decreased by PKD/PKD1 inhibition during
experimental pancreatitis (Thrower et al., 2011). Here we show
that PKD/PKD1 inhibition in cerulein-inducedpancreatitis results
in a more rapid and greater extent of decrease in the protein lev-
els of XIAP, c-FLIPs, and survivin. Using cell culture approaches,
we found that down-regulation of PKD/PKD1 decreased protein
levels of XIAP, c-FLIPs, and survivin whereas up-regulation of
PKD/PKD1 expression enhanced protein levels of these IAPs, sup-
porting a role for PKD/PKD1 in the regulation of the IAPs.We also
showed that inhibition of XIAP expression (as a representative of
IAPs) significantly reduced necrosis while enhancing apoptosis
and caspase activation, further supporting a mechanism by which
PKD/PKD1 regulates cell death pathways through its effects on
protein levels of IAPs. Although NF-κB is responsible for at least
some of changes in IAPs levels caused by PKD inhibition observed
in the in vivo pancreatitis experiments, the complete mechanism
of reduction in IAPs with PKD inhibition may include changes
in degradation rates as well. Further studies will be needed to
investigate whether PKD regulates rates of degradation of IAPs.
Receptor-interacting protein kinase 1, a key regulator of pro-
grammed necrosis in many diseases including acute pancreatitis
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FIGURE 10 | A scheme summarizing the role of PKD/PKD1 in multiple
pathological processes of pancreatitis and the mechanisms of PKD
activation mediating cell death in pancreatitis. CCK/cerulein-induced
PKD activation increases the levels of anti-apoptotic proteins (XIAP, c-FLIPs,
and survivin). The increased anti-apoptotic proteins suppress caspase
activation and apoptosis. Caspases inhibition also results in decreased
cleavage/inactivation of RIP1, thus, leading to increased necrosis and the
severity of pancreatitis. This cell necrotic death response is blocked when
PKD is inhibited. PKD inhibition promotes apoptosis and decreases
necrosis. Thus, PKD inhibition will switch cell death away from necrosis. As
we previously reported, PKD/PKD1 also mediates other pathological
processes of pancreatitis, including NF-κB activation and inflammatory
response, zymogen activation, and amylase secretion. All these effects
indicate that PKD/PKD1 may represent a potential therapeutic target in
pancreatitis. PKD inhibition decreases the severity of pancreatitis.
(Lin et al., 1999; Chan et al., 2003; Meylan and Tschopp, 2005; Fes-
tjens et al., 2007; Galluzzi et al., 2009; He et al., 2009; Moquin
and Chan, 2010; Trichonas et al., 2010), has been known to
be cleaved/inactivated by caspase-3 and -8. Our studies indi-
cate that PKD1/IAPs signaling pathway regulates the expression
and inactivation of RIP1 in pancreatitis. For example, (i) phar-
macological inhibition of PKD/PKD1 led to earlier and greater
degradation/inactivation of RIP1 in cerulein-induced pancreatitis.
(ii) Up-regulation of PKD1 expression, which enhanced protein
levels of XIAP and survivin, resulted in increased RIP1 pro-
duction as well as decreased degradation. (iii) Down-regulation
of PKD1 with PKDsiRNAs, which decreased the protein lev-
els of these IAPs, promoted RIP1 cleavage/inactivation. (iv)
Genetic inhibition of XIAP expression markedly increased RIP1
cleavage/inactivation in the pancreatic acinar cells. These results
indicate that PKD/PKD1 regulates RIP1 expression and inactiva-
tion through the IAPs.
Development of specific PKD inhibitors has been of intense
interest during recent years following the recognition of mul-
tiple physiological and pathophysiological effects of PKDs in
human. Of note, although PKD/PKD1 is activated in many cases
through PKCs (Berna et al., 2007; Yuan et al., 2008; Chen et al.,
2009; Rozengurt, 2011; Thrower et al., 2011), selectively target-
ing each PKC isotype is difficult in pancreatitis and other dis-
orders because of the number of PKC isotypes activated and
the lack of isoform-specific PKC inhibitors. Our previous stud-
ies demonstrated that at least four PKC isotypes (α, δ, ε, ζ)
are activated during pancreatitis. PKD/PKD1, as a convergent
point, integrates the signaling from these PKCs to mediate zymo-
gen activation, amylase secretion, and NF-κB activation (Yuan
et al., 2008; Thrower et al., 2011), which are key signals involved
in pancreatic injury and the inflammatory response of pancre-
atitis. The findings presented here show that PKD/PKD1 plays
a critical role in the mechanisms of cell death in pancreatitis.
Thus, PKD/PKD1 inhibition will have beneficial effects for pre-
venting multiple pathological processes of pancreatitis including
inappropriate intracellular digestive enzyme activation, inflam-
mation, and cell necrotic death response, as summarized in
Figure 10.
In summary, our studies demonstrate that PKD/PKD1 is a
key mediator of necrosis in acute pancreatitis through its effects
on IAPs, caspases, and RIP1. The mechanisms are described in
Figure 10. PKD activation in pancreatitis increases the levels
of anti-apoptotic proteins, XIAP, c-FLIPs, and survivin, which
suppress caspase activation and inhibit apoptosis. Caspase inhi-
bition also results in decreased cleavage/inactivation of RIP1,
thus, leading to increased necrosis and severity of pancreatitis.
This cell necrotic death response is blocked when PKD is inhib-
ited. PKD inhibition promotes apoptosis and decreases necrosis.
Thus, PKD inhibition switches cell death away from necrosis
and ameliorates the severity of pancreatitis. The critical role
of PKD/PKD1 in necrotic cell death and in other pathological
processes of pancreatitis, as we previously identified, all indicates
that PKD/PKD1 may represent a potential therapeutic target in
pancreatitis.
ACKNOWLEDGMENTS
The authors would like to thank Dr. Aurelia Lugea for discus-
sion and help in animal experiment design and TUNEL staining,
Dr. Olga Mareninova for discussion of acinar cell staining. The
authors also thank Dr. Edwin Thrower (Yale University School
of Medicine) and Dr. Christopher R. Ireson and his group at
the Cancer Research Technology Discovery Laboratories, London,
UK for providing us with CRT0066101. This study was sup-
ported by the Department of Veterans Affairs Merits Grant and
the Southern California Research Center for Alcoholic Liver and
Pancreatic Diseases (NIH Grant P50-A11999); UCLA Center of
Excellence in Pancreatic Diseases (NIH Grant 1P01AT0003960-
01); and Lee Summer Student Research Award from Southern
California Research Center for Liver and Pancreatic Diseases (to
Tanya Tan).
www.frontiersin.org March 2012 | Volume 3 | Article 60 | 15
Yuan et al. PKD1 regulates death-signaling in pancreatitis
REFERENCES
Beil, M., Leser, J., Lutz, M. P.,
Gukovskaya, A., Seufferlein, T.,
Lynch, G., Pandol, S. J., and Adler,
G. (2002). Caspase 8-mediated
cleavage of plectin precedes F-
actin breakdown in acinar cells
during pancreatitis. Am. J. Phys-
iol. Gastrointest. Liver Physiol. 282,
G450–G460.
Berna, M. J., Hoffmann, K. M., Tapia,
J. A., Thill, M., Pace, A., Mantey, S.
A., and Jensen, R. T. (2007). CCK
causes PKD1 activation in pancre-
atic acini by signaling through PKC-
delta and PKC-independent path-
ways. Biochim. Biophys. Acta 1773,
483–501.
Bhatia, M. (2004a). Apoptosis of pan-
creatic acinar cells in acute pancre-
atitis: is it good or bad? J. Cell. Mol.
Med. 8, 402–409.
Bhatia, M. (2004b). Apoptosis versus
necrosis in acute pancreatitis. Am.
J. Physiol. Gastrointest. Liver Physiol.
286, G189–G196.
Bhatia, M., Wallig, M. A., Hofbauer, B.,
Lee, H. S., Frossard, J. L., Steer, M.
L., and Saluja, A. K. (1998). Induc-
tionof apoptosis inpancreatic acinar
cells reduces the severity of acute
pancreatitis. Biochem. Biophys. Res.
Commun. 246, 476–483.
Bratton, S. B., Walker, G., Srinivasula,
S. M., Sun, X. M., Butterworth,
M., Alnemri, E. S., and Cohen, G.
M. (2001). Recruitment, activation
and retention of caspases-9 and -3
by Apaf-1 apoptosome and associ-
ated XIAP complexes. EMBO J. 20,
998–1009.
Chan, F. K., Shisler, J., Bixby, J.
G., Felices, M., Zheng, L., Appel,
M., Orenstein, J., Moss, B., and
Lenardo, M. J. (2003). A role for
tumor necrosis factor receptor-2
and receptor-interacting protein in
programmed necrosis and antivi-
ral responses. J. Biol. Chem. 278,
51613–51621.
Chen, L. A., Li, J., Silva, S. R., Jack-
son, L. N., Zhou, Y., Watanabe, H.,
Ives, K. L., Hellmich, M. R., and
Evers, B. M. (2009). PKD3 is the pre-
dominant protein kinase D isoform
in mouse exocrine pancreas and
promotes hormone-induced amy-
lase secretion. J. Biol. Chem. 284,
2459–2471.
Chiu, T. T., Leung, W. Y., Moyer, M.
P., Strieter, R. M., and Rozengurt,
E. (2007). Protein kinase D2 medi-
ates lysophosphatidic acid-induced
interleukin 8 production in non-
transformed human colonic epithe-
lial cells through NF-kappaB. Am.
J. Physiol. Cell Physiol. 292, C767–
C277.
Deveraux, Q. L., and Reed, J. C. (1999).
IAP family proteins-suppressors
of apoptosis. Genes Dev. 13,
239–252.
Doppler, H., Storz, P., Li, J., Comb, M.
J., and Toker, A. (2005). A phospho-
rylation state-specific antibody rec-
ognizes Hsp27, a novel substrate of
protein kinase D. J. Biol. Chem. 280,
15013–15019.
Edinger, A. L., and Thompson, C. B.
(2004). Death by design: apop-
tosis, necrosis and autophagy.
Curr. Opin. Cell Biol. 16,
663–669.
Festjens, N., Berghe, T. V., Cornelis, S.,
andVandenabeele, P. (2007). RIP1, a
kinase on the crossroads of a cell’s
decision to live or die. Cell Death
Differ. 14, 400–410.
Fielitz, J., Kim, M. S., Shelton, J. M.,
Qi, X., Hill, J. A., Richardson, J. A.,
Bassel-Duby, R., and Olson, E. N.
(2008). Proc. Natl. Acad. Sci. U. S.
A. 105, 3059–3063.
Galluzzi, L., Kepp, O., and Kroemer, G.
I. (2009). RIP kinases initiate pro-
grammed necrosis. J. Mol. Cell. Biol.
1, 8–10.
Gukovskaya, A. S., Gukovsky, I., Jung,
Y., Mouria, M., and Pandol, S.
J. (2002). Cholecystokinin induces
caspase activation and mitochondr-
ial dysfunction in pancreatic acinar
cells. roles in cell injury processes
of pancreatitis. J. Biol. Chem. 277,
22595–22604.
Gukovskaya, A. S., Gukovsky, I., Zani-
novic, V., Song, M., Sandoval,
D., Gukovsky, S., and Pandol,
S. J. (1997). Pancreatic acinar
cells produce, release, and respond
to tumor necrosis factor-alpha.
role in regulating cell death and
pancreatitis. J. Clin. Invest. 100,
1853–1862.
Gukovskaya, A. S., and Pandol, S.
J. (2004). Cell death pathways
in pancreatitis and pancre-
atic cancer. Pancreatology 4,
567–586.
Harikumar, K. B., Kunnumakkara, A.
B., Ochi, N., Tong, Z., Deorukhkar,
A., Sung, B., Kelland, L., Jamieson,
S., Sutherland, R., Raynham, T.,
Charles, M., Bagherzadeh, A., Fox-
ton, C., Boakes, A., Farooq, M.,
Maru, D., Diagaradjane, P., Matsuo,
Y., Sinnett-Smith, J., Gelovani, J.,
Krishnan, S., Aggarwal, B. B., Rozen-
gurt, E., Ireson, C. R., and Guha,
S. (2010). A novel small molecule
inhibitor of protein kinase D blocks
pancreatic cancer growth in vitro
and in vivo. Mol. Cancer Ther. 9,
1136–1146.
He, S., Wang, L., Miao, L., Wang, T., Du,
F., and Wang, X. (2009). Receptor
interacting protein kinase-3 deter-
mines cellular necrotic response to
TNF-alpha. Cell 137, 1100–1111.
Heemskerk, F. M., Chen, H. C., and
Huang, F. L. (1993). Protein kinase
C phosphorylates Ser152, Ser156
and Ser163 but not Ser160 of
MARCKS in rat brain. Biochem.
Biophys. Res. Commun. 190,
236–241.
Jacamo, R., Sinnett-Smith, J., Rey,
O., Waldron, R. T., and Rozen-
gurt, E. (2008). Sequential pro-
tein kinase C (PKC)-dependent and
PKC-independent protein kinase
D catalytic activation via Gq-
coupled receptors: differential regu-
lation of activation loop SER(744)
and SER(748) phosphorylation. J.
Biol. Chem. 283, 12877–12887.
Kaiser, A. M., Saluja, A. K., Sengupta,
A., Saluja, M., and Steer, M. L.
(1995). Relationship between sever-
ity, necrosis, and apoptosis in five
models of experimental acute pan-
creatitis. Am. J. Physiol. 269, C1295–
C1304.
Kawakami, H., Tomita, M., Matsuda,
T., Ohta, T., Tanaka, Y., Fujii, M.,
Hatano, M., Tokuhisa, T., and Mori,
N. (2005). Transcriptional activation
of survivin through the NF-kappaB
pathway by human T-cell leukemia
virus type I tax. Int. J. Cancer 115,
967–974.
Kerbauy, D. M., Lesnikov, V., Abbasi,
N., Seal, S., Scott, B., and Deeg,
H. J. (2005). NF-kappaB and
FLIP in arsenic trioxide (ATO)-
induced apoptosis in myelodysplas-
tic syndromes (MDSs). Blood 106,
3917–3925.
Krantic, S., Mechawar, N., Reix, S.,
and Quirion, R. (2007). Apoptosis-
inducing factor: a matter of neuron
life and death. Prog. Neurobiol. 81,
179–196.
Krueger, A., Schmitz, I., Baumann, S.,
Krammer, P. H., and Kirchhoff, S.
(2001). Cellular FLICE-inhibitory
protein splice variants inhibit dif-
ferent steps of caspase-8 activation
at the CD95 death-inducing signal-
ing complex. J. Cell Biochem. 276,
20633–20640.
Lin, Y., Devin, A., Rodriguez, Y.,
and Liu, Z. G. (1999). Cleav-
age of the death domain kinase
RIP by caspase-8 prompts TNF-
induced apoptosis. Genes Dev. 13,
2514–2526.
Mareninova, O. A., Sung, K. F.,
Hong, P., Lugea, A., Pandol, S. J.,
Gukovsky, I., and Gukovskaya, A.
S. (2006). Cell death in pancreati-
tis: caspases protect from necrotiz-
ing pancreatitis. J. Biol. Chem. 281,
3370–3381.
Matthews, S. A., Rozengurt, E., and
Cantrell,D. (1999).Characterization
of serine 916 as an in vivo autophos-
phorylation site for protein kinase
D/Protein kinaseCmu. J. Biol. Chem.
274, 26543–26549.
Meylan, E., and Tschopp, J. (2005). The
RIP kinases: crucial integrators of
cellular stress. Trends Biochem. Sci.
30, 151–159.
Moquin, D., and Chan, F. K. (2010).
The molecular regulation of pro-
grammed necrotic cell injury. Trends
Biochem. Sci. 35, 434–441.
Pahl, H. L. (1999). Activators and tar-
get genes of Rel/NF-kappaB tran-
scription factors. Oncogene 18,
6853–6866.
Pandol, S. J., Saluja, A. K., Imrie,
C. W., and Banks, P. A. (2007).
Acute pancreatitis: bench to the
bedside. Gastroenterology 132,
1127–11251.
Peter,M. E. (2004). The flip side of FLIP.
Biochem. J. 382, e1–e3.
Piiper, A., Leser, J., Lutz, M. P., Beil,
M., and Zeuzem, S. (2001). Subcel-
lular distribution and function of
Rab3A-D in pancreatic acinarAR42J
cells. Biochem. Biophys. Res. Com-
mun. 287, 746–751.
Ramsden, J. J. (2000). MARCKS: a
case of molecular exaptation? Int. J.
Biochem. Cell Biol. 32, 475–479.
Rozengurt, E. (2011). Protein kinase D
signaling: multiple biological func-
tions in health and disease. Physiol-
ogy 26, 23–33.
Schoenberg, M. H., Büchler, M., Gas-
par, M., Stinner, A., Younes, M.,
Melzner, I., Bültmann, B., and Beger,
H. G. (1990). Oxygen free radicals in
acute pancreatitis of the rat. Gut 31,
1138–1143.
Sharlow, E. R., Giridhar, K. V., LaValle,
C. R., Chen, J., Leimgruber, S.,
Barrett, R., Bravo-Altamirano, K.,
Wipf, P., Lazo, J. S., and Wang,
Q. J. (2008). Potent and selec-
tive disruption of protein kinase
D functionality by a benzox-
oloazepinolone. J. Biol. Chem. 283,
33516–33526.
Stehlik, C., Martin, R., Kumabashiri,
I., Schmid, J. A., Binder, B. R.,
and Lipp, J. (1998). NF-κB reg-
ulated X-chromosome-linked IAP
gene expression protects endothelial
cells from TNF-α induced apoptosis.
J. Exp. Med. 188, 211–216.
Storz, P., Doppler, H., and Toker, A.
(2004). Protein kinase Cdelta selec-
tively regulates protein kinase D-
dependent activation of NF-kappaB
in oxidative stress signaling. Mol.
Cell Biol. 24, 2614–2626.
Sung, K. F., Odinokova, I. V., Mareni-
nova, O. A., Rakonczay, Z. Jr.,
Frontiers in Physiology | Gastrointestinal Sciences March 2012 | Volume 3 | Article 60 | 16
Yuan et al. PKD1 regulates death-signaling in pancreatitis
Hegyi, P., Pandol, S. J., Gukovsky,
I., and Gukovskaya, A. S. (2009).
Prosurvival Bcl-2 proteins stabilize
pancreatic mitochondria and pro-
tect against necrosis in experimen-
tal pancreatitis. Exp. Cell Res. 315,
1975–1989.
Tang, D., Lahti, J. M., and Kidd,
V. J. (2000). Caspase-8 activa-
tion and bid cleavage contribute
to MCF7 cellular execution in a
caspase-3-dependent manner dur-
ing staurosporine-mediated apopto-
sis. J. Biol. Chem. 275, 9303–9307.
Thome, M., and Tschopp, J. (2001).
Regulation of lymphocyte prolifer-
ation and death by FLIP. Nat. Rev.
Immunol. 1, 50–58.
Thrower, E. C., Yuan, J., Usmani, A.,
Liu,Y., Jones,C., Samantha,N.,Min-
ervini, S. N., Alexandre, M., Pandol,
S. J., and Guha, S. (2011). A novel
protein kinaseD inhibitor attenuates
early events of experimental pan-
creatitis in isolated rat acini. Am.
J. Physiol. Gastrointest. Liver Physiol.
300, G120–G129.
Trauzold, A., Schmiedel, S., Sipos, B.,
Wermann, H., Westphal, S., Roder,
C., Klapper, W., Arlt, A., Lehnert,
L., Ungefroren, H., Johannes, F. J.,
and Kalthoff, H. (2003). PKCmu
prevents CD95-mediated apoptosis
and enhances proliferation in pan-
creatic tumour cells. Oncogene 22,
8939–8947.
Trichonas, G., Murakami, Y., Thanos,
A., Morizane, Y., Kayamaa, M.,
Debouckc, C. M., Hisatomi, T.,
Miller, J. W., and Vavvas, D. G.
(2010). Receptor interacting protein
kinases mediate retinal detachment-
induced photoreceptor necrosis and
compensate for inhibition of apop-
tosis. Proc. Natl. Acad. Sci. U.S.A.
107, 21695–21700.
Yuan, J., Lugea, A., Zheng, L., Gukovsky,
I., Edderkaoui, M., Rozengurt, E.,
and Pandol, S. J. (2008). Pro-
tein kinase D1 mediates NF-κB
activation induced by cholecys-
tokinin and cholinergic signaling in
pancreatic acinar cells. (2008). Am.
J. Physiol. Gastrointest. Liver Physiol.
295, G1190–G1201.
Yuan, J., and Rozengurt, E. (2008).
PKD, PKD2, and p38 MAPK medi-
ate Hsp27 serine-82 phosphoryla-
tion induced by neurotensin in
pancreatic cancer PANC-1 cells. J.
Cell Biochem. 103, 648–662.
Zou, T., Rao, J. N., Guo, X., Liu,
L., Zhang, H. M., Strauch, E. D.,
Bass, B. L., and Wang, J. Y. (2004).
NF-kappaB-mediated IAP expres-
sion induces resistance of intesti-
nal epithelial cells to apoptosis after
polyamine depletion. Am. J. Physiol.
Cell Physiol. 286, C1009–C1018.
Conflict of Interest Statement: The
authors declare that the research was
conducted in the absence of any com-
mercial or financial relationships that
could be construed as a potential con-
flict of interest.
Received: 30 January 2012; paper pending
published: 13 February 2012; accepted:
29 February 2012; published online: 27
March 2012.
Citation: Yuan J, Liu Y, Tan T, Guha
S, Gukovsky I, Gukovskaya A and Pan-
dol SJ (2012) Protein kinase D regu-
lates cell death pathways in experimen-
tal pancreatitis. Front. Physio. 3:60. doi:
10.3389/fphys.2012.00060
This article was submitted to Frontiers
in Gastrointestinal Sciences, a specialty of
Frontiers in Physiology.
Copyright © 2012 Yuan, Liu, Tan, Guha,
Gukovsky, Gukovskaya and Pandol. This
is an open-access article distributed under
the terms of the Creative Commons Attri-
bution Non Commercial License, which
permits non-commercial use, distribu-
tion, and reproduction in other forums,
provided the original authors and source
are credited.
www.frontiersin.org March 2012 | Volume 3 | Article 60 | 17
